When to Refer a Patient to Urology with an Elevated PSA
Patients should be referred to urology for PSA values above 4.0 ng/ml or for significant PSA velocity changes, specifically increases of 1.0 ng/ml or more in a year. 1, 2
Primary Referral Criteria
- PSA > 4.0 ng/ml: This has been the standard threshold for urologic referral and consideration of prostate biopsy since the introduction of PSA testing 2, 3
- PSA velocity changes:
Additional Referral Considerations
- Abnormal digital rectal examination (DRE): Any nodule, asymmetry, or areas of increased firmness warrant immediate referral regardless of PSA level 4, 2
- PSA in "gray zone" (2.6-4.0 ng/ml): Consider referral in high-risk patients (family history, African American race) 2
- For patients on testosterone replacement therapy:
Important Clinical Considerations
- PSA is not cancer-specific: Elevations can occur with prostatitis, benign prostatic hyperplasia, and after procedures 5, 6
- Consider repeat testing before referral: If there's suspicion of prostatitis or recent urologic procedures, consider repeating PSA after 4-6 weeks 7
- Avoid common pitfalls:
- Don't dismiss elevated PSA in asymptomatic patients - 32% of prostate cancers would be missed if relying on abnormal DRE alone 3
- Don't automatically attribute elevated PSA to infection without clear symptoms - empiric antibiotics without evidence of infection don't reliably lower PSA 7
- Don't delay referral for significant PSA velocity changes (≥1.0 ng/ml/year) even if absolute PSA is within normal range 4, 1
Algorithm for PSA Management
- PSA > 4.0 ng/ml: Immediate urology referral 2, 3
- PSA 2.6-4.0 ng/ml: Consider referral in high-risk patients 2
- Any PSA with abnormal DRE: Immediate urology referral 4, 2
- PSA velocity ≥ 1.0 ng/ml/year: Urology referral regardless of absolute value 4, 1
- PSA velocity 0.7-0.9 ng/ml/year: Repeat PSA in 3-6 months; refer if further increase 4
Remember that early detection through appropriate referral can significantly impact mortality and quality of life outcomes for patients with prostate cancer 3, 8.